NEW YORK ( TheStreet) -- Nektar Therapeutics (Nasdaq: NKTR) hit a new 52-week low Monday as it is currently trading at $4.79, below its previous 52-week low of $4.81 with 32,185 shares traded as of 9:51 a.m. ET. Average volume has been 1.3 million shares over the past 30 days.

Nektar has a market cap of $569.2 million and is part of the health care sector and drugs industry. Shares are down 62.3% year to date as of the close of trading on Friday.

Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms.
  • Practice your NKTR trading strategies and win cash in our stock game.

TheStreet Ratings rates Nektar as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. You can view the full Nektar Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.